Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

17,556 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Adding pegylated interferon to entecavir for hepatitis B e antigen-positive chronic hepatitis B: A multicenter randomized trial (ARES study).
Brouwer WP, Xie Q, Sonneveld MJ, Zhang N, Zhang Q, Tabak F, Streinu-Cercel A, Wang JY, Idilman R, Reesink HW, Diculescu M, Simon K, Voiculescu M, Akdogan M, Mazur W, Reijnders JG, Verhey E, Hansen BE, Janssen HL; ARES Study Group. Brouwer WP, et al. Among authors: zhang n, zhang q. Hepatology. 2015 May;61(5):1512-22. doi: 10.1002/hep.27586. Epub 2015 Feb 27. Hepatology. 2015. PMID: 25348661 Clinical Trial.
Hepatitis B core-related antigen levels are associated with response to entecavir and peginterferon add-on therapy in hepatitis B e antigen-positive chronic hepatitis B patients.
van Campenhout MJ, Brouwer WP, van Oord GW, Xie Q, Zhang Q, Zhang N, Guo S, Tabak F, Streinu-Cercel A, Wang J, Pas SD, Sonneveld MJ, de Knegt RJ, Boonstra A, Hansen BE, Janssen HL. van Campenhout MJ, et al. Among authors: zhang n, zhang q. Clin Microbiol Infect. 2016 Jun;22(6):571.e5-9. doi: 10.1016/j.cmi.2016.02.002. Epub 2016 Feb 18. Clin Microbiol Infect. 2016. PMID: 26898481 Free article.
Long-term follow-up of patients treated with entecavir and peginterferon add-on therapy for HBeAg-positive chronic hepatitis B infection: ARES long-term follow-up.
van Campenhout MJH, Brouwer WP, Xie Q, Guo S, Chi H, Qi X, Tabak F, Streinu-Cercel A, Wang JY, Zhang NP, Idilman R, Reesink HW, Diculescu M, Simon K, Akdogan M, Mazur W, de Knegt RJ, Verhey E, Hansen BE, Janssen HLA; ARES Study Group. van Campenhout MJH, et al. J Viral Hepat. 2019 Jan;26(1):109-117. doi: 10.1111/jvh.12997. Epub 2018 Sep 27. J Viral Hepat. 2019. PMID: 30187612
CAPS1 Suppresses Tumorigenesis in Cholangiocarcinoma.
Weng S, Janssen HLA, Zhang N, Tang W, Bai E, Yang B, Dong L. Weng S, et al. Among authors: zhang n. Dig Dis Sci. 2020 Apr;65(4):1053-1063. doi: 10.1007/s10620-019-05843-9. Epub 2019 Sep 27. Dig Dis Sci. 2020. PMID: 31562609
17,556 results
You have reached the last available page of results. Please see the User Guide for more information.